Pharmaceuticals Analyst Karnauskas discusses Vertex’s VX-548 and other acute and longer-acting pain drugs on an Analyst/Industry conference call to be held on April 3 at 10 am. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex announces acceptance of NDS for exagamglogene autotemcel
- Vertex Pharmaceuticals advances inaxaplin into Phase 3 portion of trial
- Are Investors Vastly Underestimating CRISPR Therapeutics Stock (NASDAQ:CRSP)?
- Truist pharmaceuticals analyst holds an analyst/industry conference call
- Vertex Pharmaceuticals announces FDA clearance of VX-407 IND